Decided to re-discuss reimbursement criteria for Mylotarg

On the 26th, the cancer disease review committee decided, BOSULIF. succeeded in setting standards as the second-line treatment

Acute myeloid leukemia treatment drug Mylotarg decided to re-discuss setting reimbursement standards.

 

This drug received attention as the first Antibody-Drug Conjugate (ADC) treatment, but in May of last year, the Cancer Disease Review Committee failed to establish reimbursement standards.

 

The HIRA (Chief Director Kang Jung-gu) announced that it decided to re-discuss Mylotarg as a result of the review of the reimbursement standards for drugs used in cancer patients, which were reviewed at the 5th Cancer Disease Review Committee in 2023 held on the 26th.

 

This drug, licensed in Korea in December 2021, is an ADC consisting of a CD33-targeting monoclonal antibody and calicheamicin, a cytotoxic drug, and blocks cancer cell growth through a mechanism that acts on cells expressing the CD33 antigen that appears in 90% of all AML patients.

 

induce extinction.

 

In a clinical trial on 271 patients with acute myeloid leukemia, the Mylotarg+Daunorubicin+Cytarabine combination group showed a median event-free survival of 17.3 months, which was approximately 7.8 months longer than the daunorubicin+Cytarabine combination group's 9.5 months.

 

As the deliberation committee decided to re-discuss it, attention is paid to whether it will succeed in setting the salary standard through data supplementation.

 

BOSULIF, a treatment for Philadelphia chromosome inactive chronic myelogenous leukemia, failed to set reimbursement standards as a first-line treatment but succeeded as a second-line treatment.

 

Therefore, criteria for use were established for Ph+ CML in the chronic phase, AP, or acute phase (BP) who showed resistance or intolerance to previous therapies.

 

Oxaliplatin + Capecitabine combination therapy, which has been expanding the reimbursement standard, has also been set as adjuvant therapy after surgery for patients who have received chemotherapy before or after surgery for rectal cancer.

 

On the other hand, Besremi, which is used for polycythemia vera that is resistant or intolerant to hydroxyurea, failed to establish reimbursement standards.